Medium-sized drugmakers hit by poor sales and net profit last year

Published: 2010-03-15 06:59:00

Updated: 2010-03-15 06:59:00

Overall, medium-sized pharmaceutical firms ranging from 50 to 200 billion in sales suffered from poor revenues and/or earnings last year due chiefly to the government’s anti-rebate measures, according to Yakup Shinmoon.

Korea’s leading pharmaceutical manufacturers, such as Dong-A, Green Cross,...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK